Entera Bio (ENTX)
(Delayed Data from NSDQ)
$2.25 USD
-0.06 (-2.60%)
Updated May 31, 2024 04:00 PM ET
After-Market: $2.25 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ENTX 2.25 -0.06(-2.60%)
Will ENTX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ENTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ENTX
Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
Immunovant (IMVT) Falls as Q4 Earnings Miss, Pipeline in Focus
ENTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data
Other News for ENTX
The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
Entera Bio appoints Wagman as Key Clinical Advisor, SAB member
Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024
Entera Bio to present Phase 1 data from EB612 at ENDO 2024